FDA Approves Zurnai Auto-Injector for the Emergency Treatment of Known or Suspected Opioid Overdose
Purdue Pharma L.P. announced the U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the Zurnai (nalmefene injection) Auto-Injector. Zurnai (zur nye) is a single-dose auto-injector that delivers 1.5mg of nalmefene hydrochloride per actuation.
- Zurnai is indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. Zurnai is intended for immediate administration as emergency therapy in settings where opioids may be present. Zurnai is not a substitute for emergency medical care.
Source: Purdue Pharma L.P.
